West Pharmaceutical Services Reports Strong Q3 Results and Provides 2026 Revenue and EPS Guidance
West Pharmaceutical Services (WST) reported third-quarter financial results that exceeded market expectations, driven by a 12% organic revenue growth. The company achieved quarterly revenues of $874 million and an adjusted earnings per share (EPS) of $2.66. Looking ahead to 2026, management issued optimistic guidance, forecasting annual revenue between $3.41 billion and $3.42 billion. Additionally, the company expects adjusted EPS for 2026 to fall within the range of $9.38 to $9.48, supported by sustained double-digit growth in High Value Product (HVP) components.
Tickers: $WST